Evaluate the Role of Adding Amaryl to Non-Insulin Dependent Diabetes Mellitus Patients Unresponsive to Maximum Dose Metformin & Thiazolidinedione
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00044447|
Recruitment Status : Completed
First Posted : August 30, 2002
Last Update Posted : June 19, 2008
|Condition or disease||Intervention/treatment||Phase|
|Diabetes Mellitus, Non-Insulin-Dependent||Drug: Glimepiride||Phase 3|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||170 participants|
|Intervention Model:||Parallel Assignment|
|Official Title:||A Double-Blind, Placebo-Controlled, Parallel Group Comparison Study to Evaluate the Role of the Addition of Amaryl to NIDDM Patients Not Responding to Maximum Dose Metformin and Thiazolidinedione Therapy|
|Study Start Date :||May 2001|
|Study Completion Date :||September 2002|
- Change in HbA1C from baseline to Week 26.
- Incidence of hypoglycemia.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00044447
|United States, Texas|
|Dallas Diabetes & Endocrine Center|
|Dallas, Texas, United States, 75230|
|Study Director:||ICD CSD||Sanofi|